By a judgement dated 28 September 2010, the Tribunal de Grande Instance of Paris held that claims 1, 2 and 3 of the French designation of Merck & Co. Ltd’s Patent EP 0 724 444 were invalid for being excluded from the scope of patentability in accordance with the provisions of Article 53(c) EPC 2000 (former Article 52  (4) EPC 1973). The court held that the invention the subject-matter of main claim 1 was only a new dosage regime ranging from 0.05 to 1 mg) of an already known compound (finasteride) in an already known therapeutic application (the treatment of hyperandrogenic conditions and especially the treatment of androgenic alopecia). A mere new dosage regime is not a second medical use but a therapeutic method excluded from patentability pursuant to Article 53  (c) EPC 2000.

An interesting case decided by Technical Board of Appeal 3.5.5 in May 2009 strives to put an end to the (occasional) practice of some applicants and/or their European representatives of trying to again pursue in a divisional application a claim that was finally rejected in the parent application. The decision further develops existing case law…

In this decision the EBoA held that sexually crossing of plants is an ‘essential biological process’ within the meaning of Art. 53(b) EPC. Any claim that contains a step of sexually crossing therefore falls within the exception to patentability, whether or not additional technical measures (e.g. selecting) would be present. Only if a claim relates…

On the occasion of a dispute opposing the Institut Pasteur and two Chiron companies, the French Cour de Cassation rendered on 14 December 2010 an interesting decision which confirms the existing case law on three points : the “file wrapper estoppel” theory, the contributory infringement and the infringement by equivalence.

The Hong Kong Polytechnic University filed a patent application for a system and process for monitoring railway tracks by means of optical fibres. The applicant argued that, whereas document D1 related to railway monitoring systems using optical fibre sensors, the skilled person, being, as railway engineers, of very conservative nature, would only consider conventional electromagnetic…

SK Telecom filed a patent application for a system and method for financial transactions, wherein a user was allowed to load money in his account on a host computer. The examining division refused to grant a patent for lack of inventive step as the invention related to a straightforward technical implementation of an administrative banking…

On 8 October 2010, the Cour d’Appel of Paris rendered a interesting decision about the interpretation of the wording of one of the settlement agreements which have been concluded between Institut Pasteur and the American health authority (DHHS/NIH) in order to put an end to the various disputes which opposed them concerning the paternity of the HIV-1/VIH retrovirus’ discovery and the patents relating thereto. The question at stake was to determine if a gp 110 protein was the subject-matter of the said settlement agreement so that Abbott, as a sublicensee of the NIH, could validly exploit in France that gp 110 protein in its detecting kits. Otherwise Abbott would have been an infringer of the Institut Pasteur’s European patents.

The Enlarged Board of Appeal answered the question referred to it by the Board of Appeal in J 2/08. The Enlarged Board of Appeal held that after a decision to refuse a European patent application, the application remains pending, in the sense that a divisional application can be validly filed, until the expiry of the…